Concord Medical Services Holding Ltd. ADR Stock

$5.02

2.45% day before yesterday

NYSE, Dec 27, 10:10 pm CET

ISIN

US2062771058

Symbol

CCM

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Health service provider

Overview Dividends Analysts Charts News Strategies

Concord Medical Services Holding Ltd. ADR Stock price

$5.02

-22.31 81.63% 5Y

NYSE, Closing price Fri, Dec 27 2024

+0.12 2.45%

ISIN

US2062771058

Symbol

CCM

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Health service provider

Key metrics

Market capitalization	$14.13m
Enterprise Value	$1.02b
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	15.58
P/S ratio (TTM) P/S ratio	0.22
P/B ratio (TTM) P/B ratio	negative
Revenue growth (TTM) Revenue growth	-25.83%
Revenue (TTM) Revenue	$65.26m
EBIT (operating result TTM) EBIT	$-61.80m
EPS (TTM) EPS	$-12.04
Short interest	0.85%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Concord Medical Services Holding Ltd. ADR Stock Analysis

Unlock Scores for Free

??

Financial data from Concord Medical Services Holding Ltd. ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	65 65	26% 26% 100%
- Direct Costs	76 76	25% 25% 117%
Gross Profit	-11 -11	23% 23% -17%
- Selling and Administrative Expenses	35 35	7% 7% 53%
- Research and Development Expense	- -	- -
EBITDA	-46 -46	11% 11% -70%
- Depreciation and Amortization	16 16	17% 17% 25%
EBIT (Operating Income) EBIT	-62 -62	13% 13% -95%
Net Profit	-52 -52	22% 22% -80%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Concord Medical Services Holding Ltd. ADR Stock News

Neutral

PRNewsWire

●

20 days ago

Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate

BEIJING , Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People's Republic of China has granted approval to the application for the Registration Certi...

Neutral

PRNewsWire

●

about 2 months ago

Concord Medical Schedules 2024 Annual Meeting of Shareholders

BEIJING , Nov. 13, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2024 annual general meeting of shareholders (the "Meeting") on December 27, 2024, at 10:00 a.m. (Beijing Time).

Neutral

PRNewsWire

●

3 months ago

Concord Medical Reports Financial Results for the First Half of 2024

BEIJING , Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024 [1].

More Concord Medical Services Holding Ltd. ADR News

Company Profile

Concord Medical Services Holding Ltd. engages in the operation of radiotherapy and diagnostic imaging centers. It provides radiotherapy and diagnostic equipment leasing services to hospitals; and sale of medical equipment and the provision of radiotherapy and diagnostic equipment leasing and management services to hospitals, It operates through Network Business and Hospital Business segments. The company was founded on November 27, 2007 and is headquartered in Beijing, China.

Head office	Cayman Islands
CEO	Jianyu Yang
Employees	727
Founded	2007
Website	www.concordmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now